Topline Results of Phase III Study in Acute Ischemic Stroke
(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and
Placebo
NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and PAION AG today announced
topline results ofthe DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with thecompound Desmoteplase. The Phase III study was designed toinvestigate the improvement of clinical outcome in patients withacute ischemic stroke treated with Desmoteplase within 3 to 9 hoursafter onset of...
deCODE Announces Positive Topline Results for Phase I Study of
DG051 for the Prevention of Heart Attack
REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced positive top-line results from itsPhase I multiple dose clinical trial of DG051, which the company isdeveloping for the prevention of heart attack. In the study, arandomized, double-blind, multi- dose, ascending dose,placebo-controlled clinical trial, a total of 40 healthy subjectswere exposed to DG...
CombinatoRx Provides Topline Results from Phase 2 RA Study with
CRx-139 and Very Low Dose Prednisolone
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced preliminary results ofa phase 2 clinical trial studying CRx-139 (a synergisticcombination of 3mg prednisolone and the antidepressant paroxetine)and 3mg prednisolone alone, in patients with rheumatoid arthritis(RA). This trial served two important purposes. One purpose was todetermine th...
CV Therapeutics Announces Topline MERLIN TIMI-36 Results
- Full study results will be presented at the American College ofCardiology's Scientific Session - PALO ALTO, Calif., March 06, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that an analysis of unblindeddata from the MERLIN TIMI-36 study of ranolazine shows there was noadverse trend in death or arrhythmias in patients on ranolazine.The study did not meet the primary...